Today: 21 May 2026
Browse Category

SHA:603501 18 January 2026 - 1 February 2026

OmniVision Integrated Circuits Group Class A stock (603501) dipped Friday — what traders watch next week

OmniVision Integrated Circuits Group Class A stock (603501) dipped Friday — what traders watch next week

OmniVision Class A shares fell 1.37% to 121.20 yuan in Shanghai trading Friday. Norges Bank cut its stake in the company’s Hong Kong shares to 4.89% after selling 76,500 shares. Axera Semiconductor filed for a HK$2.96 billion Hong Kong IPO, with Tencent and Qiming among cornerstone investors. Montage Technology targets a HK$7.04 billion secondary listing, with pricing set for February 6.
1 February 2026
··
OmniVision Integrated Circuits (603501) stock: Monday’s Shanghai open in focus after Nvidia China trip report

OmniVision Integrated Circuits (603501) stock: Monday’s Shanghai open in focus after Nvidia China trip report

OmniVision shares in Shanghai are set to open after reports that Chinese customs have blocked Nvidia’s H200 AI chip, with Nvidia CEO Jensen Huang in Shanghai as Beijing weighs approval. OmniVision closed Friday at 129.40 yuan, up 0.43%. The company raised $615.9 million in Hong Kong this month, saying 70% will fund R&D. Investors await Shanghai’s open and any signals from the Nvidia-China situation.
26 January 2026
···
OmniVision Integrated Circuits (603501) stock: the convertible-bond call setting up Monday’s trade

OmniVision Integrated Circuits (603501) stock: the convertible-bond call setting up Monday’s trade

OmniVision’s Class A shares closed up 1.84% at 130.83 yuan in Shanghai on Friday. The company said it will not lower the conversion price on its “Weier” convertible bond, keeping it at 159.38 yuan per share until at least July 15, despite hitting a reset trigger. Investors are watching for dilution risk and funding pressures as the stock reopens Jan. 19.
18 January 2026
·

Stock Market Today

  • CyberTech Systems Earnings Raise Cash Flow Concerns Amid Market Stability
    May 20, 2026, 8:56 PM EDT. CyberTech Systems and Software Limited (NSE:CYBERTECH) posted earnings that met market expectations but revealed an accrual ratio of 0.53, indicating weaker free cash flow relative to profit. This financial metric, which measures non-cash earnings, signals potential challenges for upcoming profits as free cash flow of ₹76 million lagged behind reported profit of ₹304.3 million for the year ending March 2026. Despite a 28% annual growth in earnings per share (EPS) over three years, the decline in cash conversion may raise investor caution. The company's accrual ratio improved last year, suggesting the current shortfall could be temporary, but shareholders are advised to monitor cash flow trends closely against profitability for a clearer outlook.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop